Drug Identification System

PillID

← Drug Encyclopedia 🌙

Uses & FDA Indications

Escitalopram carries FDA approval for two primary indications: major depressive disorder (MDD) in adults and adolescents aged 12 and older, and generalized anxiety disorder (GAD) in adults. It is one of the few antidepressants with an approved adolescent indication for depression.

Beyond its approved uses, escitalopram is commonly prescribed off-label for panic disorder, social anxiety disorder (social phobia), obsessive-compulsive disorder (OCD), post-traumatic stress disorder (PTSD), and premenstrual dysphoric disorder (PMDD). Its favorable side-effect profile makes it a frequent first-line choice.

How It Works

Escitalopram works by selectively inhibiting the serotonin transporter (SERT) protein on presynaptic neurons. Under normal physiology, SERT reabsorbs serotonin from the synaptic cleft back into the neuron that released it — a process called reuptake. By blocking SERT, escitalopram increases the amount of serotonin available in the synapse to bind postsynaptic receptors.

Increased serotonergic neurotransmission in key brain circuits — including limbic regions involved in mood, fear, and reward — is thought to underlie its antidepressant and anxiolytic effects. However, mood improvement typically lags several weeks behind the immediate pharmacological action, suggesting that downstream neuroplastic changes (such as increased BDNF signaling and hippocampal neurogenesis) are important components of the therapeutic effect.

Compared to its racemic parent compound citalopram, escitalopram is roughly twice as potent at SERT and has minimal affinity for histamine, dopamine, muscarinic, or adrenergic receptors, which helps explain its cleaner side-effect profile.

Side Effects

Common

• Nausea (most common early in treatment, typically resolves within 1–2 weeks)
• Insomnia or somnolence
• Headache
• Dry mouth
• Increased sweating
• Sexual dysfunction (decreased libido, delayed ejaculation, anorgasmia)
• Fatigue or drowsiness
• Diarrhea or constipation

Serious

• Serotonin syndrome — agitation, hyperthermia, tachycardia, neuromuscular abnormalities (risk heightened with serotonergic co-medications)
• QTc interval prolongation — particularly at higher concentrations; risk increased in patients with cardiac disease or electrolyte abnormalities
• Suicidal ideation — black box warning applies in patients under 25, particularly early in treatment or after dose changes
• Hyponatremia — especially in elderly patients; mediated by SIADH
• Activation syndrome — restlessness, agitation, or insomnia that may precede emergence of suicidal thoughts
• Abnormal bleeding — SSRIs inhibit platelet aggregation; risk increases with NSAIDs or anticoagulants

Drug Interactions

Drug / Class	Interaction	Clinical Significance
MAO Inhibitors (phenelzine, selegiline)	Risk of life-threatening serotonin syndrome	Contraindicated — 14-day washout required
Other serotonergic agents (tramadol, triptans, linezolid)	Additive serotonergic effects; serotonin syndrome risk	High — avoid or monitor closely
QT-prolonging drugs (antipsychotics, some antibiotics)	Additive QTc prolongation risk	High — ECG monitoring recommended
NSAIDs / Aspirin	Increased GI bleeding risk due to impaired platelet function	Moderate — consider GI protection (PPI)
Warfarin	Possible increased anticoagulant effect; monitor INR	Moderate
Lithium	Enhanced serotonergic effects; monitor lithium levels	Moderate — use cautiously
CYP2C19 inhibitors (omeprazole, fluconazole)	Increased escitalopram plasma levels	Low–moderate — dose adjustment may be needed

Warnings & Contraindications

Contraindications: Concurrent use with MAO inhibitors or pimozide. Known hypersensitivity to escitalopram or citalopram.

Discontinuation syndrome: Abrupt discontinuation may cause dizziness, electric shock sensations ("brain zaps"), irritability, nausea, and flu-like symptoms. Gradual tapering under medical supervision is strongly recommended.

Angle-closure glaucoma: SSRIs can trigger acute angle-closure glaucoma in predisposed individuals due to pupillary dilation effects.

Neonatal adaptation syndrome: Neonates exposed to SSRIs late in pregnancy may experience respiratory distress, cyanosis, feeding difficulty, and irritability. Weigh risks and benefits during pregnancy.

Frequently Asked Questions

How long does escitalopram take to work?

Most patients notice some improvement in sleep, energy, and appetite within the first 1–2 weeks. However, meaningful improvement in mood and anxiety typically requires 4–6 weeks of consistent use, and full therapeutic benefit may take up to 8–12 weeks. It is important not to stop early if initial improvement is modest.

Can I drink alcohol while taking escitalopram?

Alcohol and escitalopram both depress the central nervous system. Combining them can worsen sedation and may counteract the antidepressant effect. Most clinicians advise limiting or avoiding alcohol entirely during treatment.

Is escitalopram habit-forming?

Escitalopram is not considered habit-forming and is not a controlled substance. However, physical dependence can develop, meaning abrupt discontinuation may cause withdrawal-like symptoms. This is distinct from addiction and is managed by gradual tapering.

Does escitalopram cause weight gain?

Weight changes are possible but vary among individuals. Some patients report modest weight gain over long-term use, while others experience no change or slight weight loss early in treatment. Discuss any significant weight changes with your prescriber.

→ SSRI Side Effects Guide → Depression Medications Guide → Anxiety Medications Guide